13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001496201
Total reported value
$766.5M
$766.5M
113 檔
13.2%
The Q1 2025 SEC filing reveals that Sphera Funds Management LTD. held a total portfolio value of $766.5M, covering 113 public equity positions.
In Q1 2025, Sphera Funds Management LTD. adopted a defensive or profit-taking posture, trimming 19 positions and completely liquidating 97 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 5.56% | +1.19% | +0.19% | |
| 2 | TLT | Ishares 20+ Year Treasury Bd | ETF-Gov Bonds | 5.35% | -0.12% | — | |
| 3 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 4.71% | +0.20% | +20.47% | |
| 4 | SNY | Sanofi-adr | Stock-Healthcare | 3.89% | -0.56% | -20.81% | |
| 5 | NVMI | Nova Ltd. | Stock-Other | 3.85% | -1.90% | +33.09% | |
| 6 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 2.96% | — | -22.22% | |
| 7 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 2.92% | -0.51% | -59.50% | |
| 8 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.65% | -0.13% | +38.73% | |
| 9 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 2.32% | — | +59.65% | |
| 10 | LLY | Eli Lilly & Co | Stock-Healthcare | 2.22% | -0.06% | -11.37% | |
| 11 | CLDX | Celldex Therapeutics Inc | Stock-Other | 2.12% | -0.06% | +7.11% | |
| 12 | PRAX | Praxis Precision Medicines I | Stock-Other | 2.10% | +0.55% | NEW | |
| 13 | JNJ | Johnson & Johnson | Stock-Healthcare | 2.02% | -0.16% | -24.34% | |
| 14 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 1.89% | +0.05% | +20.39% | |
| 15 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 1.80% | -0.26% | -9.58% | |
| 16 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.70% | -0.59% | +144.15% | |
| 17 | AMZN | Amazon.com Inc | Stock-Consumer Disc | 1.60% | -1.06% | EXIT | |
| 18 | ABBV | Abbvie Inc | Stock-Healthcare | 1.46% | -0.05% | -11.68% | |
| 19 | PHVS | Pharvaris N.V. | Stock-Other | 1.39% | — | -1.11% | |
| 20 | ORA | Ormat Technologies Inc | Stock-Utilities | 1.37% | -0.81% | +6.33% | |
| 21 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.34% | +0.43% | -28.60% | |
| 22 | META | Meta Platforms Inc-class A | Stock-Comm Services | 1.32% | — | -52.56% | |
| 23 | NVS | Novartis Ag-sponsored Adr | Stock-Healthcare | 1.28% | +0.12% | — | |
| 24 | MRK | Merck & Co. Inc. | Stock-Healthcare | 1.23% | +0.05% | — | |
| 25 | ORA 2.5 07-15-27 SEPTBond | Ormat Technologies Inc | Bond | 1.20% | — | — | |
| 26 | NICE | Nice LTD - Spon Adr | Stock-Tech | 1.18% | -0.10% | EXIT | |
| 27 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 1.16% | -0.37% | — | |
| 28 | SEDG | Solaredge Technologies Inc | Stock-Tech | 1.15% | -0.43% | EXIT | |
| 29 | ETNBGBP | 89bio Inc | Stock-Other | 1.04% | — | +11.11% | |
| 30 | ✓ | Merus N V | Stock-Other | 1.03% | — | -18.39% | |
| 31 | ✓ | Immatics NV | Stock-Other | 0.96% | -0.14% | — | |
| 32 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 0.91% | -1.37% | EXIT | |
| 33 | MAZE | Maze Therapeutics Inc | Stock-Other | 0.90% | +0.55% | — | |
| 34 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.83% | — | -9.38% | |
| 35 | SVRA | Savara Inc | Stock-Other | 0.82% | -0.03% | +5.99% | |
| 36 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 0.81% | — | +40.50% | |
| 37 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.79% | +0.12% | +39.36% | |
| 38 | ANNX | Annexon Inc | Stock-Other | 0.78% | — | +41.94% | |
| 39 | JANX | Janux Therapeutics Inc | Stock-Other | 0.78% | — | +84.16% | |
| 40 | HELP | Cybin Inc | Stock-Other | 0.77% | +0.65% | -2.02% | |
| 41 | IMVT | Immunovant Inc | Stock-Other | 0.77% | — | — | |
| 42 | NVDA | Nvidia CORP | Stock-Tech | 0.74% | — | — | |
| 43 | RZLT | Rezolute Inc | Stock-Other | 0.72% | — | -7.24% | |
| 44 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.72% | — | — | |
| 45 | AMGN | Amgen Inc | Stock-Healthcare | 0.72% | -0.07% | — | |
| 46 | BIIB | Biogen Inc | Stock-Healthcare | 0.72% | +2.85% | — | |
| 47 | ACOG | Alpha Cognition Inc | Stock-Other | 0.70% | +0.02% | -3.71% | |
| 48 | VIGL | Vigil Neuroscience Inc | Stock-Other | 0.66% | — | +6.79% | |
| 49 | NTLA | Intellia Therapeutics Inc | Stock-Other | 0.62% | — | -18.24% | |
| 50 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 0.61% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SNDX | Syndax Pharmaceuticals Inc | +4.1% | +20.47% | Add |
| 2 | TEVA | Teva Pharmaceutical-sp Adr | +3.7% | +0.19% | Trim |
| 3 | SNY | Sanofi-adr | +0.9% | -20.81% | Trim |
| 4 | META | Meta Platforms Inc-class A | +0.7% | -52.56% | Trim |
| 5 | AMZN | Amazon.com Inc | +0.7% | -41.53% | Add |
| 6 | ✓ | Merus N V | +0.6% | -18.39% | Trim |
| 7 | SEDG | Solaredge Technologies Inc | +0.6% | -17.54% | Add |
| 8 | DYN | Dyne Therapeutics Inc | +0.3% | +39.36% | Trim |
| 9 | NTLA | Intellia Therapeutics Inc | 0% | -18.24% | Add |
| 10 | IONS | Ionis Pharmaceuticals Inc | -0.1% | — | Trim |
| 11 | NICE | Nice LTD - Spon Adr | -0.1% | -21.64% | Trim |
| 12 | ✓ | Lava Therapeutics NV | -0.2% | -61.67% | Trim |
| 13 | SWTXUSD | Springworks Therapeutics Inc | -0.6% | -47.99% | Trim |
| 14 | LLY | Eli Lilly & Co | -0.6% | -11.37% | Trim |
| 15 | HOWL | Werewolf Therapeutics Inc | -0.7% | — | Trim |
| 16 | KURA | Kura Oncology Inc | -0.7% | -43.69% | Trim |
| 17 | MSFT | Microsoft CORP | -0.8% | -79.43% | Trim |
| 18 | FATE | Fate Therapeutics Inc | -0.9% | — | Add |
| 19 | BIIB | Biogen Inc | -1% | — | Trim |
| 20 | ABBV | Abbvie Inc | -1.3% | -11.68% | Trim |
| 21 | AZNN | Astrazeneca Plc-spons Adr | -1.7% | -22.22% | Trim |
| 22 | JNJ | Johnson & Johnson | -2.5% | -24.34% | Trim |
| 23 | XENE | Xenon Pharmaceuticals Inc | -3.3% | -49.91% | Trim |
| 24 | MRK | Merck & Co. Inc. | -6.9% | — | Trim |
| 25 | XBI | Ss Spdr S&p Biotech ETF | — | EXIT | Sold out |
| 26 | GNRC | Generac Holdings Inc | — | EXIT | Sold out |
| 27 | ENPH | Enphase Energy Inc | — | EXIT | Sold out |
| 28 | IGV | Ishares Expanded Tech-softwa | — | EXIT | Sold out |
| 29 | XLK | Ss Technology Select Sector | — | EXIT | Sold out |
| 30 | FVRR | Fiverr International Ltd. | — | EXIT | Sold out |
| 31 | IWM | Ishares Russell 2000 ETF | — | EXIT | Sold out |
| 32 | TLT | Ishares 20+ Year Treasury Bd | — | NEW | New buy |
| 33 | CCCC | C4 Therapeutics Inc | — | EXIT | Sold out |
| 34 | TAN | Invesco Solar ETF | — | EXIT | Sold out |
| 35 | EPIEUR | Essa Pharma Inc | — | EXIT | Sold out |
| 36 | KRNT | Kornit Digital Ltd. | — | EXIT | Sold out |
| 37 | ZLAB | Zai Lab Ltd-adr | — | EXIT | Sold out |
| 38 | NVMI | Nova Ltd. | — | NEW | New buy |
| 39 | LPSNUSD | Liveperson Inc | — | EXIT | Sold out |
| 40 | PTGX | Protagonist Therapeutics Inc | — | EXIT | Sold out |
| 41 | VTGNUSD | Vistagen Therapeutics Inc | — | EXIT | Sold out |
| 42 | AUDC | AudioCodes Ltd. | — | EXIT | Sold out |
| 43 | BBIO | Bridgebio Pharma Inc | — | NEW | New buy |
| 44 | KYMR | Kymera Therapeutics Inc | — | EXIT | Sold out |
| 45 | VRNS | Varonis Systems Inc | — | EXIT | Sold out |
| 46 | ✓ | Oncorus Inc | — | EXIT | Sold out |
| 47 | CRNX | Crinetics Pharmaceuticals In | — | EXIT | Sold out |
| 48 | RARE | Ultragenyx Pharmaceutical In | — | NEW | New buy |
| 49 | ATERUSD | Aterian Inc | — | EXIT | Sold out |
| 50 | AFRM | Affirm Holdings, Inc. | — | EXIT | Sold out |
According to official SEC Form 13F filings, Sphera Funds Management LTD. reported a total U.S. public equity portfolio value of $766.5M across 113 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TEVA, TLT, SNDX) accounted for 13.2% of total reported equity market value during Q1 2025.
Top New Position Initiated
TLT
市值: $23.2M
Top Position Liquidated / Trimmed
XBI
前期市值: $84.6M
During Q1 2025, Sphera Funds Management LTD.'s top holdings by market value included TEVA (5.6%)、TLT (5.3%)、SNDX (4.7%). The largest single position, TEVA, represented 5.6% of total portfolio value.
In Q1 2025, Sphera Funds Management LTD. made 200 total portfolio adjustments, initiating 79 new buys, adding to 5 positions, trimming 19 holdings, and fully liquidating 97 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.